UPDATED June 12, 2014, with results from an additional trial.
Boston Scientific (NYSE:BSX) this week touted positive data from a pair of clinical studies using its Vercise deep-brain stimulation device to treat Parkinson’s disease.
The Medical Device Business Journal — Medical Device News & Articles | MassDevice
UPDATED June 12, 2014, with results from an additional trial.
Boston Scientific (NYSE:BSX) this week touted positive data from a pair of clinical studies using its Vercise deep-brain stimulation device to treat Parkinson’s disease.
Boston Scientific (NYSE:BSX) kicked off a new registry evaluating deep brain stimulation in treatment of Parkinson’s disease.
Boston Scientific (NYSE:BSX) said it won CE Mark approval in the European Union for its Vercise deep-brain stimulation device for treating the movement disorder called dystonia.
Living Cell Technologies successfully treated its 1st patient in a clinical trial evaluating a new implantable regenerative therapy for treating Parkinson’s disease. The patient, the 1st enrolled in LCT’s Phase I clinical trial, was said to be recovering well in the days after the surgery.
MASSDEVICE ON CALL — For the 1st time Mazor Robotics’ (PINK:MZRTF) Renaissance robot-assisted surgical system system was used to to treat a Parkinson’s patient, implanting a battery-sized neurostimulator that delivers mild electrical stimulation to targeted areas of the brain.
The 1st patient was implanted with a new iteration of Medtronic’s deep brain stimulation device that delivers therapy while simultaneously recording brain activity.
The company is touting its Activa PC+S Deep Brain Stimulation system as a game-changer in the way neurological and psychological diseases are treated, thanks to its simultaneous treating and monitoring capabilities.
Boston Scientific (NYSE:BSX) said it launched a U.S. clinical trial of its Vercise deep-brain stimulation treatment for patients with Parkinson’s disease and touted interim results from a European study of the device.
By Sony Salzman
MASSDEVICE ON CALL —Senior officials at the Department of Veterans Affairs will see reduced salaries and fewer bonuses in 2014 after the House voted to send a message about the tomes of backlogged veteran’s disability claims.
The more than 800,000 backlogged veteran’s disability claims have been a hot-button issue across party lines, and the new budget beefs up allocated money for processing these claims while cutting down on senior official’s compensation.
Patients with Parkinson’s disease may benefit from receiving neurostimulating brain implants earlier in the course of the disease, according to researchers.
Treatment with neurostimulators, which delivery mild electrical pulses to targeted areas in the brain, are already standard for patients with advanced Parkinson’s disease, but researchers suggested that it may benefit patients "at an earlier stage than current recommendations suggest."